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The juvenile form of neuronal ceroid lipofuscinoses (JNCLs), or Batten disease, results from mutations in the CLN3 gene,
and it is characterized by the accumulation of lipopigments in the lysosomes of several cell types and by extensive
neuronal death. We report that the yeast model for JNCL (btn1-) that lacks BTN1, the homologue to human CLN3, has
increased resistance to menadione-generated oxidative stress. Expression of human CLN3 complemented the btn1-
phenotype, and equivalent Btn1p/Cln3 mutations correlated with JNCL severity. We show that the previously reported
decreased levels of L-arginine in btn1- limit the synthesis of nitric oxide (NO) in both physiological and oxidative stress
conditions. This defect in NO synthesis seems to suppress the signaling required for yeast menadione-induced apoptosis,
thus explaining btn1- phenotype of increased resistance. We propose that in JNCL, a limited capacity to synthesize NO
directly caused by the absence of Cln3 function may contribute to the pathology of the disease.
INTRODUCTION
Neuronal ceroid lipofuscinoses (NCLs) are a group of inher-
ited lysosomal storage disorders with an overall incidence of
up to 1 in 12,500 live births, making it the most common
type of childhood neurodegenerative disease (Goebel, 1995).
The different NCL forms are characterized by massive neu-
ronal death and accumulation of lipopigments in the lyso-
somes of several cell types (Goebel, 1997). Juvenile NCL
(JNCL; Batten or Spielmeyer–Vogt–Sjogren disease; OMIM
204200) is the most common form, and it presents a disease
course marked by vision loss, psychomotor deterioration,
epileptic seizures, and premature death in the mid-20s
(Boustany, 1992). JNCL is caused by mutations in CLN3, a
gene identified in 1995 (Lerner et al., 1995). Saccharomyces
cerevisiae harbors a gene, designated BTN1, that encodes a
nonessential protein 39% identical and 59% similar to hu-
man Cln3 (Pearce and Sherman, 1997), and deletion of BTN1,
btn1- has provided a useful model for JNCL research
(Pearce et al., 1999a,b; Kim et al., 2003). In btn1-, it has been
shown that pH homeostasis is altered (Pearce et al., 1999c)
and that a decrease in vacuolar arginine transport results in
a depletion of intracellular arginine levels (Kim et al., 2003).
Expression of human Cln3 in btn1- complemented these
defects, demonstrating that the function of these proteins is
conserved (Pearce et al., 1999c; Kim et al., 2003). These find-
ings allowed the identification of primary biochemical de-
fects in JNCL that were later confirmed in more complex
animal models (Golabek et al., 2000; Kim et al., 2003; Pearce
et al., 2003; Ramirez-Montealegre and Pearce, 2005). In spite
of these and other advances in understanding the disease, an
association between the known biochemical alterations and
the accumulation of storage bodies or the process of neuro-
degeneration has not yet been established.
Oxidative stress has been widely reported in neurodegen-
erative conditions such as amyotrophic lateral sclerosis and
Alzheimer’s and Parkinson’s diseases as a possible cause of
cell death and as a possible effector of apoptosis (Dexter et al.,
1989; Lassmann et al., 1995; Mochizuki et al., 1996; Beal et al.,
1997; Smith et al., 1997; Good et al., 1998; Pedersen et al., 1998;
Butterfield et al., 2002), although, in most cases, it remains
unclear whether oxidative stress is the primary cause, a medi-
ator, or a downstream consequence of the neurodegenerative
process. In NCL, studies presenting increased lipid peroxida-
tion and mitochondrial dysfunction support the hypothesis
that oxidative stress might also be implicated in this pathology
(Jolly et al., 2002; Guarneri et al., 2004). Nonetheless, no alter-
ations in antioxidant enzymes were detected in several tested
tissues from human patients (Marklund et al., 1981; Garg et al.,
1982).
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We report that btn1- has increased resistance to menadi-
one indicating that a lack of Btn1p results in an increased
tolerance to oxidative stress. This phenotype is specifically
attributable to the lack of Btn1p, and it can be complemented
by the human Cln3. Moreover, we show that this resistance
to oxidative stress is a direct cause of decreased l-arginine
levels in btn1- limiting the production of nitric oxide (NO),
which functions, at high concentrations, as a signal for ap-
optosis. Our results link a primary biochemical alteration
caused by the absence of Btn1p or Cln3 with a possible
mechanism of cell death. Because cell lines derived from
JNCL patients also have reduced intracellular l-arginine
levels (Ramirez-Montealegre et al., 2005), it is possible that
the limitation in NO production we observe in btn1- might
also occur in cells from JNCL patients. Due to the impor-
tance of NO signaling this defect might have an important
role in JNCL pathology.
MATERIALS AND METHODS
Yeast Strains and Media
S. cerevisiae strains used in this study are based in the BY wild-type reference
strain purchased from Euroscarf (Frankfurt, Germany). The genetic back-
ground of the strains used is listed in Table 1. Double deletion of SOD1/BTN1
was done by homologous recombination of a BTN1 deletion cassette contain-
ing the hygromycin phosphotransferase (hph) gene on Y16913. Double dele-
tion of BTN1/SOD2 and BTN1/CTT1 was generated by mating YO1364 with
Y16605 and YO1364 with Y14718. The resulting diploid strains were sporu-
lated and dissected. Single and double deletions were confirmed by polymer-
ase chain reaction (PCR). Strains were maintained in YEPD agar medium
containing yeast extract (0.5%, wt/vol), peptone (1%, wt/vol), glucose (2%,
wt/vol), and agar (2%, wt/vol). Cells were routinely grown at 26°C with
aeration on a mechanical shaker (160 rpm) in defined YNB medium contain-
ing glucose (0.5%, wt/vol) and yeast nitrogen base without amino acids
(0.67%, wt/vol) supplemented with leucine, uracil, histidine, and lysine at the
final concentrations of 30, 10, 5, and 5 mg/l, respectively. Growth was
monitored by turbidity monitoring at 640 nm (OD640) on a WPA Lightwave
S2000 UV/Vis spectrophotometer (Isogen Life Science, Ijsselstein, The Neth-
erlands). For the experimental assays, cells were grown until early logarithmic
phase.
Menadione Treatments
Menadione was prepared immediately before treatment at a concentration of
10 mM in a solution of 98% ethanol, 0.2% cetrimide. Treatments were per-
formed by direct addition of menadione solution at the indicated concentra-
tions to cell suspensions, and controls were performed by the addition of
equal volume of 98% ethanol, 0.2% cetrimide solution.
Cell Viability (Colony-forming Ability)
Cells harvested by centrifugation at 4°C (1000  g for 5 min) were washed,
counted, and diluted to a concentration of 3  106 cells/ml in 10 ml of YNB
medium. Immediately before the addition of the stress agent (t0) and after
different times of treatment (tn), 100 l of cell suspension was diluted 1–10
three times and plated on YEPD plates. Colonies were counted after 48-h
incubation at 30°C. Results of survival percentage were obtained using as
reference the number of colonies counted in t0 plates versus the number of
colonies obtained in tn plates.
Flow Cytometry Analysis
Fluorescence analysis was carried out by flow cytometry with an EPICS XL-MCL
flow cytometer (Beckman Coulter, Fullerton, CA) equipped with an argon-ion
laser emitting a 488-nm beam at 15 mW. The green and red fluorescence were
collected through a 488-nm blocking filter, a 550-nm/long-pass dichroic with a
525-nm/band-pass and a 590-nm/long-pass with a 620-nm/band-pass, respec-
tively. An acquisition protocol was defined to measure forward scatter (FS log),
side scatter (SS log), green fluorescence (FL1 log), and red fluorescence (FL3 log)
on a four-decade logarithmic scale. Data (20,000 cells/sample) were analyzed
with the Multigraph software included in the system II acquisition software for
the EPICS XL/XL-MCL, version 1.0.
Assessment of Intracellular Reactive Oxygen Species
(ROS) Levels
Flow cytometry quantification of yeast cell populations with high ROS levels
was performed after labeling with MitoTracker Red CM-H2XRos (Invitrogen,
Carlsbad, CA) as described previously (Ludovico et al., 2002). Briefly, cells
were harvested by centrifugation, resuspended in phosphate-buffered saline
(PBS), pH 7.4, and incubated for 15 min at 37°C with 50 g/ml MitoTracker
Red CM-H2XRos. Fluorescence intensity was measured by flow cytometry,
and cells displaying higher values than a defined threshold of red fluores-
cence were considered as containing elevated intracellular ROS levels. Epi-
fluorescence microscopy visualization of intracellular ROS was performed
after labeling with dihydrorhodamine 123 (DHR123) (Invitrogen). DHR123
was added from a 1-mg/ml stock solution in ethanol, to 5  106 cells/ml
suspended in PBS, reaching a final concentration of 15 g/ml. Cells were
incubated during 90 min at 30°C in the dark, washed in PBS, and visualized
as describe previously (Almeida et al., 2007). Images were acquired in an
Olympus BX61 microscope with filter wheels to control excitation and emis-
sion wavelengths, equipped with a high-resolution Olympus DP70 digital
camera (Olympus, Tokyo, Japan).
Plasma Membrane Integrity
Plasma membrane integrity was determined by examining cellular perme-
ability to propidium iodide (PI) (Invitrogen), as described previously
(Delafuente et al., 1992). Cells were incubated with 5 g/ml PI for 15 min
Table 1. Yeast strains
Strain Genotype Source
Y10000 (wild type) BY4742;MAT; his31; leu20; lys20; ura30 Euroscarf
Y11364 (btn1-) BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4 Euroscarf
YICVS01 (btn1-) BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4 This study
Y01364 (btn1-) BY4741;MATa; his31; leu20; met150; ura30; YJL059w::kanMX4 Euroscarf
Y12098 (pep4-) BY4742;MAT; his31; leu20; lys20; ura30; YPL154c::kanMX4 Euroscarf
Y10268 (cup5-) BY4742;MAT; his31; leu20; lys20; ura30; YEL027w::kanMX4 Euroscarf
Y16913 (sod1-) BY4742;MAT; his31; leu20; lys20; ura30; YJR104c::kanMX4 Euroscarf
Y12453 (yca1-) BY4742;MAT; his31; leu20; lys20; ura30; YOR197w::kanMX4 Euroscarf
YN0001 (denoted pBTN1) BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAB1795a This study
YN0002 (denoted pCLN3) BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAB1796a This study
YN0003 BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAB2040a This study
YN0004 BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAB2041a This study
YN0005 BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAB2042a This study
YN0006 BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAB2043a This study
YN0007 BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAB2044a This study
YN0008 BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAB2045a This study
YN0010 BY4742;MAT; his31; leu20; lys20; ura30; YJL059w::kanMX4pAA1037a This study
YICVS02 (sod1-btn1-) BY4742;MAT; his31; leu20; lys20; ura30; YJR104c::kanMX4; YJL059w::hph This study
a The plasmids used are described in Pearce and Sherman (1998).
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and analyzed by flow cytometry or epifluorescence microscopy. Heat-
killed cells were used as a positive control. Cells displaying higher values
than a defined threshold of red fluorescence were considered as having
compromised plasma membrane integrity.
Assessment of Mitochondrial Function and Integrity
The charged cationic green dye rhodamine 123 (Invitrogen) was used to
assess mitochondrial function/integrity as described previously (Ludovico
et al., 2001). Cells were harvested by centrifugation and incubated with 25
g/ml rhodamine 123 for 15 min at 37°C. Fluorescence intensity was mea-
sured by flow cytometry, and cells displaying higher values than a defined
threshold of green fluorescence were considered has having compromised
mitochondrial or functional integrity.
Enzyme Activity Assays
Cells were harvested, washed, and resuspended in 2 ml of 0.05 M phosphate
buffer. To disrupt cells, 200 l of 0.5-mm-diameter glass beads was added, and
sonication for 10 times in 30-s intervals interspersed with periods of cooling in
ice. Cellular debris was removed by a 15-min centrifugation at 15,000  g, and
the supernatant was collected. Protein concentration was determined using the
Bradford method using bovine serum albumin as standard. Superoxide dis-
mutase activity was expressed in units defined as the enzyme amount able to
inhibit in 50% the velocity of cytochrome c reduction per minute and milligrams
of total protein according to McCord and Fridovich (1969). Glucose-6-phosphate
dehydrogenase (G6PDH) activity was based on the increase in absorbance at 340
nm, resulting from NADP reduction, as described previously (Postma et al.,
1989).
NO Measurements
Kinetics of NO production and decay was measured using an NO-selective
carbon fiber microelectrode coated with Nafion and o-phenylenediamine as
described previously (Ledo et al., 2002; Ferreira et al., 2005). Early log cells (9 
108) were washed, resuspended in 2 ml of 10 mM Tris-HCl, pH 7.4, and trans-
ferred to a recording cell with agitation under aerobic conditions. Amperometric
currents originated from the oxidation of NO at the electrode surface were
recorded by differential pulse amperometry (between 0.7 and 0.9 V, the range
that includes the oxidation peak of NO for the experimental conditions used)
using on a PGSAT 12 potentiostat (EcoChimie, Utrecht, The Netherlands) with
low current module installed and controlled by GPES software, version 4.9
(EcoChimie), by using a three-electrode system with a platinum wire auxiliary
electrode, a silver/silver chloride (3 M) reference electrode, and the NO-selective
carbon fiber electrode as the working electrode. The electrodes were calibrated by
a single stream flow injection analysis system using NO solutions prepared from
NO donor (diethylenetriamine-NO) or from NO gas, as described previously
(Ferreira et al., 2005). The intracellular levels of NO were assessed using the
NO-selective probe 4-amino-5-methylamino-2,7-difluorofluorescein (DAF-FM)
(Invitrogen). Cells were harvested, washed, and resuspended in PBS, pH 7.4, and
incubated for 15 min at 37°C with 5 g/ml DAF-FM. The mean fluorescence
intensity of 20,000 cells per sample was measured by flow cytometry.
Quantification of Intracellular Levels of L-Arginine
A standard procedure for extraction of total amino acids was used (Ohsumi
et al., 1988). In summary, cells at OD600 of 0.6 were harvested, washed twice
in distilled water, resuspended in AA buffer (2.5 mM potassium phosphate
buffer, pH 6.0, 0.6 M sorbitol, 10 mM glucose, and 0.2 M CuCl2) and incubated
for 10 min at 30°C. The cell suspension was collected by filtration on 0.45-m
membrane filters (Millipore, Billerica, MA) and washed four times with AA
buffer lacking 0.2 M CuCl2, representing the cytosolic fraction (Ohsumi et al.,
1988). Cells retained on the filters were resuspended in water, boiled for 15
min, and then centrifuged at 5000  g for 5 min. The supernatant was
collected as the vacuolar fraction. Both fractions were combined, and homo-
serine was added as an internal control. Arginine concentration was then
measured using high-performance liquid chromatography following the
manufacturer’s protocol (ESA, Boston, MA).
Nucleic Markers of Programmed Cell Death
Study of nuclear morphological alterations was performed by staining with
4,6-diaminilo-2-phenylindol dihydrochloride (DAPI). Cells were harvested,
washed, and then resuspended in PBS, pH 7.4, and incubated for 10 min at
37°C with 0.5 g/ml DAPI. Stained cells were washed twice with PBS and
visualized by epifluorescence microscopy (Auxioskop 2 Plus; Carl Zeiss, Jena,
Germany). DNA strand breaks were demonstrated by terminal deoxynucleo-
tidyl transferase dUTP nick-end labeling (TUNEL) assay with the In Situ Cell
Death Detection kit, fluorescein (Roche Diagnostics, Indianapolis, IN).
Assessment of Caspase-like or ASPase Activity
Study of yeast caspase-like or other ASPase activity was performed using
CaspSCREEN Flow Cytometric Analysis kit (Chemicon International, Temecula,
CA). Briefly, cells were incubated with the nonfluorescent substrate (Asp)2-
rhodamine 110 (D2R) at 37°C for 45 min, and then they were analyzed by flow
cytometry. Cells displaying higher values than a defined threshold of fluores-
cence were considered has presenting caspase-like or other ASPase activity
(Vachova et al., 2005; Almeida et al., 2007).
RESULTS
btn1- Has Increased Resistance to Oxidative Stress
To study a possible role of oxidative stress in JNCL, we
screened btn1- cells sensitivity to oxidative stress induced
by several prooxidant agents. Strains deleted in BTN1 (for
details, see Table 1) presented increased resistance to men-
adione (Figure 1A), diamide, and hydrogen peroxide (see
Supplemental Material) compared with wild-type cells. The
most marked differences were obtained for menadione treat-
ment, in which considerable loss of btn1- cells viability was
only obtained for concentrations 0.1 mM, whereas wild-
type cells were severely affected by lower menadione con-
centrations, presenting 10% of viability when treated with
0.1 mM.
To determine whether BTN1 and the human CLN3
could complement the described phenotype, we deter-
mined the viability of btn1- mutants expressing either
gene. Expression of BTN1 or CLN3 in btn1- strain (de-
noted pBTN1 and pCLN3, respectively) decreased the
viability after menadione treatment of these strains to the
wild-type level (Figure 1B), indicating the dependence of
the resistance phenotype on the lack of BTN1/CLN3. The
first report showing a Btn1p-specific phenotype in yeast
was the increased btn1- resistance to d-()-threo-2-amino-1-
[p-nitrophenyl]-1,3-propanediol (ANP), a breakdown product
of chloramphenicol with pH-dependent toxicity (Pearce and
Sherman, 1998), allowing the finding of altered pH homeosta-
sis in btn1-. This study also establishes parallels between
fundamental biological processes in yeast and characteristics in
Figure 1. Effect of 200-min menadione treat-
ment on the survival of the wild-type, btn1-,
and other mutant strains cells. (A) Percentage
of survival of wild-type (closed bars) and
btn1- (open bars) cells after treatment with
increasing concentrations of menadione rang-
ing from 0.07 to 0.16 mM. (B) Survival after
treatment with 0.1 mM menadione of btn1-
cells expressing BTN1(pBTN1) and the human
CLN3(pCLN3) and cells deleted in the vacu-
olar aspartyl protease Pep4p (pep4-) and in
the subunit of the vacuolar H-ATPase Cup5p
(cup5-). *p  0.001 versus wild-type, t test;
n  5.
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the human disease by correlating the increased resistance of
btn1- to ANP and the severity of JNCL. To further evaluate
the relationship between higher resistance to menadione and
the function of Btn1p, we tested the menadione sensitivity of
several btn1- strains expressing Btn1p with the following
amino acid replacements: R293H, L44P, L112P, E243K, V289F,
and R293C. These mutations are the counterparts of a spectrum
of Cln3 mutations known to occur in the human disease het-
erozygously with the most frequent 1.02-kb deletion (GenBank
X99832). The degree of btn1- menadione resistance is de-
creased by the expression of mutated Btn1p, and for the ma-
jority of these mutations, the degree of menadione resistance
can be correlated with JNCL severity (Table 2).
Btn1p has been shown to be a vacuolar protein (Pearce
et al., 1997; Croopnick et al., 1998). To test whether btn1-
increased menadione resistance was specific to btn1- and
not an effect attributable to general vacuolar dysfunction, we
determined the viability of strains harboring deletions in
other vacuolar proteins, namely, Cup5p (a subunit of the
vacuolar H-ATPase) and Pep4p (a vacuolar aspartyl pro-
tease). Both cup5- and pep4- strains display low resistance
to menadione similar to the wild-type control (Figure 1B).
Increased btn1- Menadione Resistance Is Associated
with Lower ROS Levels
Treatment with menadione induces the catalytic reduction
of oxygen to superoxide and other ROS, triggering mild-to-
severe cellular damage and ultimately cell death (Thor et al.,
1982; Morrison et al., 1984). For additional characterization
of the btn1- phenotype, we performed the analysis of in-
tracellular ROS levels, cell death, plasma membrane integ-
rity, and mitochondrial function/integrity along 200-min
treatment with 0.1 mM menadione (Figure 2, A–D). A slow
increase in the percentage of btn1- cells with elevated en-
dogenous ROS, resulting in a mean value of 45.2% of cells
with a positive response at the end of the treatment, was
observed. In contrast, the wild-type strain showed an abrupt
increase in cells with elevated intracellular ROS with a mean
value of 74.7% after 60-min treatment and 97.3% after 120
min (Figure 2A). These data correlate with the kinetic anal-
ysis of cell death in which the slow death rate of btn1- cells
was markedly different from the obtained for the wild-type
strain where 10% survival was observed after 120-min
treatment (Figure 2B). At this time point, the entire wild-
type population presented compromised plasma membrane
integrity, whereas only 44.9% of btn1- cell population had
lost membrane integrity (Figure 2C). Rh123 cell staining
showed that btn1- strain displayed reduced percentages of
cells with defective mitochondrial function/integrity at the
later stages of treatment compared with the wild-type strain
(Figure 2D). To assess whether the differences in intracellu-
lar ROS levels between btn1- and wild-type cells preceded
loss of cellular integrity and cell death, we visualized cells
colabeled with DHR123 and PI after 30 min of menadione
treatment (	70% viability in wild-type cells). The results
show that live wild-type cells with preserved membrane
integrity present increased intracellular ROS levels when
compared with btn1- cells (Figure 2E), suggesting the pres-
ence of a different ROS metabolism in both strains. There-
fore, to evaluate whether the lower levels of ROS in btn1-
cells were due to an increased detoxification capacity, we
have performed an evaluation of antioxidant defenses. No
significant alterations in the activity of superoxide dismuta-
ses were detected when comparing btn1- and wild-type
cells (Table 3). The activity of catalase was also not altered in
btn1- cells, even though it could only be detected in sta-
tionary phase (data not shown). Additionally, we studied
whether differences in glutathione synthesis and redox bal-
ance were involved in the btn1- phenotype. The viability of
btn1- and wild-type strains was largely reduced when cells
with inhibited glutathione biosynthesis were treated with
0.1 mM menadione (see Supplemental Material). However,
when using lower menadione concentrations, the differences
in resistance between both strains were maintained (see
Supplemental Material), indicating that glutathione synthe-
sis is not accountable for btn1- phenotype. In addition, the
activity of glucose-6-phosphate dehydrogenase, the major
source of NADPH necessary for the redox balance of gluta-
thione in yeast (Nogae and Johnston, 1990) was similar in
both strains (Table 3). These results are in accordance with
the data from DNA microarray analysis of btn1- strain that
shows no differential expression of genes encoding for en-
zymes involved in ROS detoxification (Pearce et al., 1999a).
btn1- Has Reduced NO Production, Impairing Oxidative
Signaling
Several studies suggest that NO may enhance intracellular
ROS generation (Zamzami et al., 1995; Packer et al., 1996).
Moreover, l-arginine, the substrate of the NO synthesis, is
decreased in btn1- cells (Kim et al., 2003), leading to the
hypothesis that the reduced ROS levels of btn1- are asso-
ciated to an impairment in NO synthesis. Because the syn-
thesis of NO by yeast cells is still poorly studied, we first
assessed whether nitric-oxide synthase (NOS)-like activity
could be detected in S. cerevisiae. Using a standard NOS
activity assay, we were able to detect conversion of arginine
to citrulline in yeast protein extract, partially inhibited by
1 mM nitro-l-arginine methyl ester (l-NAME) (see Supple-
mental Material). Additionally, using an NO-selective elec-
trode, we measured that yeast cells produce NO in response
to menadione, and we found that NO production was en-
hanced by l-arginine (and not by its inactive enantiomer
d-arginine; data not shown) and that it was inhibited by
l-NAME (Figure 3A). Together, these findings suggest that
an enzyme with NOS-like activity may exist in yeast. We
then studied the levels of NO production in btn1- cells.
Our results indicate that the production of NO in response
to menadione treatment is decreased in btn1-. Importantly,
this defective NO production in btn1- can be overcome by
Table 2. Correlation between the severity of different JNCL disease
variants (Munroe et al., 1997) and the percentage of survival to mena-













None 0 None 9.88 
 1.23 0
R334H 3 R293H 56.34 
 2.43 2
L101P 2 L44P 52.30 
 1.99 2
L170P 1 L112P 31.78 
 2.06 0
E295K 1 E243K 29.88 
 1.09 0
V330F 3 V289F 32.12 
 2.06 1
R334C 3 R293C 79.06 
 4.28 2
Deletion 3 Deletion 83.41 
 1.61 3
The indicated values for percentage of survival are the mean of at
least three independent assays, and SD resistance to ANP described
by Pearce and Sherman (1998) is also included.
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the addition of l-arginine, strongly suggesting that the im-
pairment in l-arginine homeostasis in btn1- underlies this
signaling defect. This result was corroborated by the use of
a fluorescent probe selective for NO, DAF-FM (Figure 3B).
Figure 2. Analysis of parameters of cell viability, integrity, and intercellular ROS levels
during menadione treatment. Kinetic analysis (200 min) of intracellular ROS levels (A),
cell death (B), plasma membrane integrity (C), and mitochondrial function/integrity (D)
in wild-type and btn1- cells exposed to 0.1 mM menadione, and visualization by
epifluorescence microscopy of loss of membrane integrity (shown in red) and intracel-
lular ROS (shown in green) in wild-type and btn1- cells after 30-min treatment with 0.1
mM menadione (E). (A) Percentage of cells with increased ROS levels, assessed by flow
cytometry using the fluorescent probe MitoTracker Red CM-H2XRos at 50 g/ml. (B)
Percentage of viable cells determined by the counting of colony-forming units. (C)
Percentage of cells with impaired cytoplasmic membrane, assessed by flow cytometric
quantification of cells labeled with propidium iodide at 5 g/ml. (D) Percentage of cells
with impaired mitochondrial function or integrity, assessed by flow cytometry using the
fluorescent probe rhodamine 123 at 25 g/ml. *p  0.001 versus wild-type, t test; n  5.
(E) Loss of membrane integrity and intracellular ROS levels were visualized by colabel-
ing cells with dihydrorhodamine 123 at 15 g/ml (green fluorescence) and propidium
iodide at 5 g/ml (red fluorescence).
Table 3. Enzyme-specific activities
Enzyme
Specific activity (U mg1 protein)
Wild type btn1-
Total superoxide dismutase (SOD) 6.29 
 0.84 5.50 
 0.43
Mn-SOD 3.73 
 0.30 4.25 
 0.39
Cu, Zn-SOD 2.57 
 0.54 1.25 
 0.90
G6PDH 47.03  103 
 2.58  103 47.62  103 
 0.69  103
The activity was measured in cell-free extract of both wild-type and btn1- cells grown in YNB liquid medium and harvested in the
exponential phase of growth. Indicated activity values are the mean of at least three assays and corresponding SD. No significant differences
were found by t test comparing the specific activity of each studied enzyme in wild-type versus btn1- cells.
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In addition, this methodology allowed detecting significant
lower NO levels under physiological conditions when com-
paring btn1- to wild-type cells (Figure 3B). Furthermore,
the analysis of btn1- and btn1- strains expressing mutated
Btn1p showed different NO levels that could be directly
correlated with the different intracellular arginine levels
present in each strain (Figure 4). Collectively, these data
imply that the defective arginine levels caused by the lack
Figure 3. Measurement of NO production in wild-type and btn1- cells. (A) Typical recording of NO production using an NO-selective
electrode after the addition of 0.1 mM menadione to 9  108 wild-type and btn1- cells in the presence or absence of 0.3 mg/ml l-arginine
and with or without preincubation with 200 mM of l-NAME. An increase of 100 pA corresponds to a production of 37 nM NO. The signal
was quenched by the addition of 150 l of packed red blood cells (RBC). (B) Forty-minute kinetic quantification by flow cytometry of the mean
fluorescence intensity of wild-type (closed bars) and btn1- (open bars) cells stained with DAF-FM, a probe specific for NO, in physiological
conditions, after treatment with 0.02 mM menadione and after the same menadione treatment in the presence of 0.3 mg/ml l-arginine or 200
mM l-NAME. *p  0.05 versus wild type, t test; n  3.
Figure 4. Correlation between the intracellu-
lar NO levels detected by labeling cells with
DAF-FM and intracellular arginine levels mea-
sured by HPCL in btn1- strains transformed
with the empty plasmid and plasmids allowing
expression of normal and point mutated Btn1p.
The linear regression graph shows results for
each strain with SE and 99% confidence interval
for n  3.
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of Btn1p function disrupt endogenous NO production in
yeast.
To study whether the endogenous production of ROS in
yeast cells upon menadione treatment was influenced by NO,
we measured the intracellular ROS levels in both strains after
menadione treatment in the presence of l-NAME. Our results
show that in the presence of l-NAME, the subpopulation of
cells with high levels of ROS is largely decreased in both strains
(Figure 5A). This is indicative that ROS generation upon men-
adione treatment is partially dependent of endogenous NO
production. To further test this hypothesis, we have used a
strain, sod1-, that has 90–95% of the total wild-type super-
oxide dismutase activity; and for this reason, it is highly sen-
sitive to redox cycling compounds (Gralla, 1997), including
menadione (Figure 5B). Most interestingly, the deletion of
BTN1 within sod1- background resulted in a marked survival
increase after menadione treatment to values similar to btn1-
cells (Figure 5B). This increased resistance of sod1- btn1- cells
was lost when treatment was performed in the presence of
l-arginine (Figure 5B). Deletion of BTN1 in strains lacking
other ROS detoxifying enzymes, namely, sod2- and ctt1- also
resulted in increased survival rates to menadione treatment
that were reverted by l-arginine addition (data not shown).
Collectively, these results suggest that the deletion of BTN1
causes a high decrease in the production of intracellular ROS
after menadione treatment to levels that are tolerated even in
Figure 5. Role of ROS in menadione-in-
duced cell death. (A) Flow cytometric study of
the production of ROS in wild-type and
btn1- cells stained with 50 g/ml Mito-
Tracker Red CM-H2XRos after 200-min treat-
ment with 0.1 mM menadione in the presence
and absence of 100 mM l-NAME. The data are
presented in the form of representative fre-
quency histograms displaying relative fluo-
rescence (x-axis) against the number of ana-
lyzed events (y-axis). (B) Survival after 200-min
treatment with 0.1 mM menadione of wild-type,
btn1-, sod1-, sod1- btn1- cells in the pres-
ence or absence of 0.4 mg/ml l-arginine.
Figure 6. Percentage of viable cells after 200-min treatment with
0.1 mM menadione in wild-type (closed bars) and btn1- (open
bars) cells after 1-h pretreatment with 100 mM l-NAME, 0.4 mg/ml
l-arginine, 0.4 mg/ml l-lysine, and 0.4 mg/ml l-alanine. *p  0.001
versus wild type, t test; n  3.
Defective Nitric Oxide Signaling in btn1-
Vol. 18, July 2007 2761
the absence of Sod1p. This phenotype was reverted by l-
arginine, suggesting that NO was mediating a burst of intra-
cellular ROS production after menadione stimulus. To study
the relevance of NO signaling in the response to menadione,
we tested the viability after menadione treatment of btn1- and
wild-type cells in the presence of l-NAME or l-arginine. Inter-
estingly, wild-type cells showed a sevenfold increase in viabil-
ity when preincubated with l-NAME, reaching values similar
to btn1- (Figure 6). In contrast, incubation with l-arginine
before menadione treatment resulted in a marked decrease in
btn1- survival to values similar to those obtained for mena-
dione treated wild-type cells (Figure 6). No effect in the growth
rate of either strain was obtained in media supplemented with
this concentration of l-arginine (data not shown). Additionally,
to test the specificity of l-arginine effect on menadione-induced
apoptosis, viability of both strains was assayed after menadi-
one treatment in the presence of similar concentrations of l-
alanine or l-lysine. These amino acids had no effect on survival
rates (Figure 6), suggesting that the observed phenomenon is
specific of l-arginine.
Defective NO Production Inhibits Menadione-induced
Apoptosis in btn1-
In a dose-dependent manner, menadione is known to induce
apoptosis in eukaryotic cells, and reactive oxygen and nitro-
gen species are thought to be important mediators in this
process (Madeo et al., 1999; Gerasimenko et al., 2002; Chen
et al., 2003). The increased resistance of btn1- cells and the
reduced levels of NO and ROS found in this strain after
Figure 7. Determination of nuclear markers of
apoptosis by fluorescence microscopy in wild-type
and btn1- cells after 200-min treatment with 0.1
mM menadione. (A) Cells visualized after TUNEL
staining; the yellow fluorescence observed in the
wild-type cells results from the colocalization of the
red probe specific for double-stranded nucleic acids
and the green probe that marks DNA breaks. (B)
Cells visualized after DAPI staining, the arrows
point to characteristic programmed cell death alter-
ations observed in the wild type, such as chromatin
condensation and nuclear fragmentation.
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menadione treatment led us to question whether menadi-
one-induced apoptosis was impaired in btn1- cells. Mena-
dione-treated cells were examined for nuclear markers of
apoptosis such as DNA fragmentation and alterations in
nuclear morphology. No DNA fragmentation could be ob-
served in btn1- cells by TUNEL assay, whereas several
wild-type cells presented a TUNEL-positive phenotype, in-
dicative of the presence of fragmented DNA (Figure 7A).
Furthermore, no nuclear morphological alterations were de-
tected in btn1- cells after menadione treatment, whereas
wild-type cells showed typical apoptotic nuclear alterations
(Figure 7B), suggesting that menadione-induced apoptosis
is largely impaired in btn1- cells. We also tested the in-
volvement of yeast metacaspase activation (Madeo et al.,
2002) in menadione-induced cell death. We measured
ASPase activity in btn1- and wild-type cells by flow cyto-
metric analysis of cells labeled with the substrate D2R, which
was shown to become fluorescent only after cleavage by
ASPase activity in yeast cells (Vachova et al., 2005; Almeida
et al., 2007). Menadione treatment induced a subpopulation of
39% of wild-type cells with high fluorescence, indicative of
ASPase activity, whereas no significant activity was detected in
btn1- cells (Figure 8A). Additionally, ASPase activity seems to
be dependent on NO production, because the treatment with
menadione in the presence of l-arginine resulted in an increase
in percentage of wild-type and btn1- cells with positive stain-
ing, whereas l-NAME decreased the positive subpopulation.
Furthermore, the survival to menadione treatment of cells de-
leted in yeast metacaspase (yca1-) is significantly increased
compared with the survival of wild-type cells (Figure 8B).
These results suggest that yeast metacaspase is involved in
menadione-induced apoptosis and that btn1- cells are unable
to activate yeast metacaspase, possibly due to the NO produc-
tion defect.
DISCUSSION
We report that btn1- results in an increased resistance to
oxidative stress induced by several prooxidant agents, in-
cluding menadione. These data describe a new phenotype
specifically attributable to the lack of BTN1, because it is
complemented by the expression of Btn1p. Phenotypic comple-
mentation also results from expression of the human Cln3,
representing additional evidence of high functional conserva-
tion between Btn1p and Cln3. Similarly to a previous report on
increased resistance of btn1- to ANP (Pearce et al., 1998), a
correlation between JNCL severity and menadione resistance
was obtained for most of the corresponding Btn1p/Cln3 mu-
tations. The potential of this type of analysis is largely affected
by the difficulties in evaluating the severity of the disease and
by the reduced number of JNCL patients that are compound
heterozygous. Nonetheless, these data constitute important
validation of the model.
Menadione, is a quinone that induces toxicity mainly by
redox cycling that consists in the catalytic reduction of
oxygen to superoxide anion and other reactive oxygen
species (Thor et al., 1982). Interestingly, following mena-
dione treatment btn1- cells show decreased levels of
intracellular ROS, while presenting no significant in-
creases in the major ROS detoxification systems compared
with wild-type cells. Because l-arginine, the substrate in
NO synthesis pathway, is decreased in btn1- cells (Kim
et al., 2003) and NO may have a role in enhancing ROS
generation within the cell (Zamzami et al., 1995; Packer
et al., 1996; Boveris et al., 2000), it was questioned whether
NO was being produced in response to menadione treat-
ment and whether it was involved in btn1- menadione-
resistance phenotype. We have shown that yeast cells
produce NO in response to oxidative stress generated by
menadione by the use of both a selective electrode and an
Figure 8. Role of yeast metacaspase in men-
adione-induced cell death. (A) Measurement
of intracellular caspase-like activity (or other
protease able to cleave substrates after Asp
residue; ASPase) by the use of D2R in wild-
type and btn1- cells after 200-min treatment
with 0.1 mM menadione in the presence or
absence of 100 mM l-NAME and 0.3 mg/ml
l-arginine. The data are presented in the form
of frequency histograms displaying relative
fluorescence (x-axis) against the number of
events analyzed (y-axis). (B) Viability of cells
deleted in the metacaspase YCA1 after 200-min
treatment with 0.1 mM menadione.
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Figure 9. Schematic model of response to menadione treatment of wild-type (A) and btn1- (B) cells. Menadione treatment of wild-type cells
(1) induces toxicity by redox cycling, generating superoxide anion and other ROS and triggering endogenous NO production (2). The
reaction between NO and superoxide anion results in the formation of other reactive species, such as peroxynitrite (3). These species can
cause increased generation of ROS in the mitochondria (Zamzami et al., 1995; Packer et al., 1996), amplifying the activation of cell death
pathways (4–7). Another consequence of mitochondrial damage can be the loss of mitochondrial membrane potential (5) and the release of
proapoptotic molecules that activates caspases and other cell death effectors (Brune, 2005) (7). The absence of Btn1p causes altered vacuolar
pH (Pearce et al., 1999c) and reduced intracellular levels of l-arginine (Kim et al., 2003). The ROS generated by menadione redox cycling in
btn1- cells (1) results in insufficient endogenous NO production due to l-arginine limitation (2). The milder concentrations of NO generated
and the consequent lower levels of ROS and reactive nitrogen species (RNS) formed are insufficient to induce the activation of mitochondrial
cell death pathways impairing the apoptotic process (3 and 4).
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NO-sensitive fluorescent probe. This finding is consistent
with studies on the function of yeast flavohemoglobin
(Yhb1p) that imply the production of NO in response to
oxidative stress (Cassanova et al., 2005). Our results also
show that the production of NO is enhanced by l-argi-
nine and inhibited by l-NAME, and we were able to
detect conversion of radioactive-labeled arginine to citrul-
line in yeast protein extracts. Together, these results sug-
gest enzymatic production of NO from l-arginine. Previ-
ous studies suggest that S. cerevisiae produces NO by a
mechanism similar to a classical NOS (Kanadia et al., 1998;
Domitrovic et al., 2003). However, bioinformatic analysis
of the S. cerevisiae genome fails to identify sequences that
are homologous to known NOS (data not shown). Thus, it
is likely that S. cerevisiae has an unknown enzyme with
NOS-like activity that is structurally unrelated to classical
NOS, similarly to what has been observed in plants (Guo
et al., 2003). A recent study shows that yeast cells generate
NO from nitrite in hypoxic conditions in a manner de-
pendent from mitochondrial respiratory chain that is con-
sequently abolished by cyanide (Castello et al., 2006).
Contrarily, the blockage of mitochondrial respiratory
chain by cyanide did not alter NO production and cell
survival after menadione treatment of wild-type and
btn1- cells (data not shown), indicating an NO produc-
tion process distinct from that described by Castello and
coworkers. Menadione-induced NO production seems to
be an essential upstream cell death signal, because the
inhibition of NO production by l-NAME treatment de-
creases the intracellular ROS levels and caspase-like ac-
tivity and largely increases wild-type cell resistance to
menadione. Although metacaspases can be kept inactive
through S-nitrosylation, a recent publication showed that
after activation, a second Cys residue that is conserved in
all metacaspases can rescue the first S-nitrosylated site,
rendering metacaspases even more active in a high NO
environment (Belenghi et al., 2007). Our results are con-
sistent with this mechanism, because we show that high
NO production triggers ROS production that has been
described to mediate metacaspase activation (Madeo et al.,
1999, 2002).
Most interestingly, NO production in btn1- cells is de-
creased both in physiological conditions and in response to
menadione treatment. This NO synthesis defect in btn1-
cells is partially overcome by the addition of high l-arginine
concentrations to the media. Furthermore, caspase-like ac-
tivity can be increased and the resistance phenotype specif-
ically reversed when btn1- cells are treated with menadi-
one in the presence of l-arginine. Because btn1- cells are
able to take up arginine from the media (Vitiello et al., 2007),
this suggests that defective NO production in btn1- cells is
due to substrate limitation and that when btn1- intracellu-
lar l-arginine levels are increased menadione-induced cell
death is restored. Supporting the importance of Btn1p in
menadione-induced cell death, we have observed a large
viability increase when deleting BTN1 in strains that are
highly sensitive to menadione, such as sod1- cells. As sum-
marized in Figure 9, collectively these data indicate that the
endogenous production of NO by S. cerevisiae cells seems to
be required for oxidative stress induced active cell death. In
particular, NO seems to be synthesized from l-arginine,
increasing the production of ROS within the cell and induc-
ing the activation of a cell death cascade. Furthermore, NO
synthesis might be limited in btn1- cells by low l-arginine
levels, possibly blocking ROS production and metacaspase
activation, causing an impairment of menadione-induced
apoptosis.
In the context of Btn1p/CLN3 function, a recent study
showed that disruption of Btn1p (btn1-) alters coupling of
the V-ATPase and proton-pumping across the vacuolar
membrane (Padilla-Lopez and Pearce, 2006). This disruption
in the electrochemical gradient between the cytosol and the
vacuole likely underlies the decreased vacuolar transport of
arginine observed in btn1- strains. It is possible that Btn1p/
CLN3 has a role in regulating intracellular levels of arginine
through active regulation of vacuolar content. Importantly,
these defects have been confirmed in human cell lines from
JNCL patients (Ramirez-Montealegre et al., 2005) where it
has been demonstrated that the absence of functional Cln3
results in defective lysosomal transport of l-arginine and in
reduced intracellular l-arginine levels. By the use of the
yeast model for JNCL, we have shown for the first time that
mutations in BTN1/CLN3 cause an l-arginine–related lim-
itation in NO synthesis both in physiological and oxidative
stress conditions. This could be a relevant advance in our
understanding of JNCL, because a defect in NO synthesis
may contribute to the extensive neuronal death observed in
the patients. Among other protective functions (for review,
see Kang et al., 2004), NO synthesis was shown to inhibit
the generation of the proapoptotic sphingolipid ceramide
(De Nadai et al., 2000) that Puranam et al. (1997) found to
be increased in the brains of JNCL patients. Therefore, de-
fective NO synthesis might be the event in JNCL pathology
that is causing ceramide accumulation and neuronal apopto-
sis. However, proving this hypothesis requires further stud-
ies targeted at in detail evaluation of NO signaling in more
complex in vitro and in vivo JNCL model systems.
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